Search Results

Infigratinib 5 mg  | 98.03%

TargetMol

Infigratinib (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.

More Information Supplier Page

Infigratinib 50 mg  | 98.03%

TargetMol

Infigratinib (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.

More Information Supplier Page

Infigratinib 10 mg  | 98.03%

TargetMol

Infigratinib (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.

More Information Supplier Page

Infigratinib 100 mg  | 98.03%

TargetMol

Infigratinib (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.

More Information Supplier Page

Procainamide hydrochloride 200 mg  | Purity Not Available

TargetMol

Procainamide Hydrochloride is the hydrochloride salt form of procainamide, an amide derivative exhibiting class 1A antiarrhythmic property and analog of procaine. Procainamide hydrochloride reversibly binds to and blocks activated (open) voltage-gated sodium channels, thereby blocks the influx of sodium ions into the cell, which leads to an increase in threshold for excitation and inhibit depolarization […]

More Information Supplier Page